Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Modified pluripotent cells

a technology of pluripotent cells and modified cells, applied in the field of regenerative cell therapy, can solve the problems that rh(d) and rh(c) antigens confer significant risk of hemolytic disease of fetus and newborns

Pending Publication Date: 2022-07-07
RGT UNIV OF CALIFORNIA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a method for creating special cells that can avoid rejection by the immune system and blood type rejection. These cells are engineered to lack certain proteins that make them vulnerable to rejection and have a universal blood type. These cells also feel less likely to be cleared by the immune system. The patent also describes cells that can be derived from these special cells and are less likely to be rejected when transplanting them into a person.

Problems solved by technology

Antibodies to Rh antigens can be involved in hemolytic transfusion reactions and antibodies to the Rh(D) and Rh(c) antigens confer significant risk of hemolytic disease of the fetus and newborn.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modified pluripotent cells
  • Modified pluripotent cells
  • Modified pluripotent cells

Examples

Experimental program
Comparison scheme
Effect test

example 1

n of Human iPSCs

[0224]The Human Episomal iPSC Line was derived from CD34+ cord blood (Cat. No. A33124, Thermo Fisher Scientific) using a three-plasmid, seven-factor (SOKMNLT; SOX2, OCT4 (POU5F1), KLF4, MYC, NANOG, LIN28, and SV40L T antigen) EBNA-based episomal system from ThermoFisher. This iPSC line is considered to have a zero footprint as there was no integration into the genome from the reprogramming event. It has been shown to be free of all reprogramming genes. The iPSCs have a normal XX karyotype and endogenous expression of pluripotent markers like OCT4, SOX2, NANOG (as shown by RT-PCR) OCT4, SSEA4, TRA-1-60 and TRA-1-81 (as shown by ICC). In directed differentiation and teratoma analyses, these hiPSCs retained their differentiation potential for the ectodermal, endodermal, and mesodermal lineages. In addition, vascular, endothelial, and cardiac lineages were derived with robust efficiencies.

[0225]Several gene-delivery vehicles for iPSC generation were successfully used, in...

example 2

n of Human HIP Cells

[0229]Hypoimmune pluripotent (HIP) cells were generated as disclosed in WO2018 / 132783 and U.S. Prov. App. Nos. 62 / 698,941, 62 / 698,965, 62 / 698,973, 62 / 698,978, 62 / 698,981, and 62 / 698,984, each of which are incorporated by reference herein in their entirety. Human Cas9 iPSC underwent 2 gene-editing steps. In the first step, CRISPR technology was performed by a combined targeting of the coding sequence of human beta-2-microglobuline (B2M) gene with the CRISPR sequence 5′-CGTGAGTAAACCTGAATCTT-3′ and the coding sequence of human CIITA gene with the CRISPR sequence 5′-GATATTGGCATAAGCCTCCC-3′. Linearized CRISPR sequence with T7 promoter was used to synthesize gRNA as per the kit's instructions (MEGAshortscript T7 Transcription Kit, Thermo Fisher). The collected in-vitro transcription (IVT) gRNA was then purified via the MEGAclear Transcription Clean-Up Kit. For IVT gRNA delivery, singularized cells were electroporated with 300 ng IVT gRNA using a Neon electroporation sy...

example 3

Rejection in Rhesus Macaque Monkeys and Pigs

[0231]10 million hypoimmunogenic B2M− / − CIITA− / − rhesus CD47 tg iPSC derived endothelial cells (expressing luciferase) were injected subcutaneously into rhesus macaque monkeys and cells were longitudinally followed using bioluminescence imaging; each animal was injected intravenously with 100 mg / ml D-luciferin (Perkin Elmer, San Jose, Calif.) via a peripheral vessel for in vivo imaging using a Xenogen IVIS® 200 Series imaging system (Caliper Life Sciences, Alameda, Calif., Cat. No. 122799). Our pre-transplant screening assays and validation studies predicted that the cells would not be rejected, resulting in stable BLI signals. The BLI-signals decreased, however, on day 6 and were not detected by day 16. In addition, “bumps” were observed on the injection sites (data not shown). Blood was drawn from the same monkeys and T cell, cytotoxic T cell, NK cell (FIG. 1A), B cell (DSA; donor specific antibodies), or macrophages activation (FIG. 1B)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
Rhaaaaaaaaaa
β-aaaaaaaaaa
Login to View More

Abstract

The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, and hypo-immune pluripotent cells that are ABO blood type O Rhesus Factor negative and evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

Description

I. CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62 / 846,399, filed May 10, 2019 and U.S. Provisional Application No. 62 / 855,499, filed May 31, 2019, each of which are incorporated herein by reference in their entirety.II. FIELD OF THE INVENTION[0002]The invention relates to regenerative cell therapy. In some embodiments, the regenerative cell therapy comprises transplanting cell lines into patients in need thereof. In some embodiments, the cell lines comprise O Rh− hypoimmunogenic pluripotent cells. In some embodiments, the regenerative cell therapy reduces the propensity for the cell transplant recipient's immune system to reject allogeneic material. In some embodiments, the regenerative cell therapy is used in the treatment of injured organs and tissue. In some embodiments, the regenerative cell therapy is used for rehabilitating damaged tissues after myocardial infarction.III. BACKGROUND ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N5/0735C12N15/113C12N5/074
CPCC12N5/0606A61K35/545C12N5/0696C12N15/1138C12N9/22C12N2310/20C12N2510/00A61K35/34C12N5/0657C12N5/069C12N2506/45C12N2506/11A61K2035/124C12N2800/80C12N15/113
Inventor SCHREPFER, SONJADEUSE, TOBIAS
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com